NDA 215358 · Novartis
Scemblix
Asciminib Hydrochloride · Oral
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Oct 29, 2021: To treat Philadelphia chromosome-positive chronic myeloid leukemia with disease that meets certain criteria
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Oct 29, 2021
Approved uses
7
Original approval plus efficacy supplements
Registered trials
44
6 Phase 3, 16 recruiting
FAERS reports
3,492
2,282 serious, 390 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 22, 2026.
SCEMBLIX is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate [see Clinical Studies (14.1)] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). Previously treated Ph+ CML in CP. Ph+ CML in CP with the T315I mutation. SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 ) Previously treated Ph+ CML in CP. ( 1 ) Ph+ CML in CP with the T315I mutation. ( 1 )
Mechanism: Asciminib is an ABL/BCR-ABL1 tyrosine kinase inhibitor. Asciminib inhibits the ABL1 kinase activity of the BCR::ABL1 fusion protein, by binding to the ABL myristoyl pocket. In studies conducted in vitro or in animal models of CML, asciminib showed activity against wild-type BCR::ABL1 and several mutant forms of the kinase, including the T315I mutation.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 25, 2025 Supplement 12 · Efficacy OrphanLetterLetterLabel
- Oct 2, 2025 Supplement 10 · Efficacy OrphanLabelLetter
- Oct 29, 2024 Supplement 8 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Oct 29, 2024 Supplement 9 · Efficacy · priority review OrphanLetterLabel
- Oct 12, 2022 Supplement 1 · Efficacy · priority review OrphanLetterLabel
- Oct 29, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetter
- Oct 29, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
3 products under this application
- SCEMBLIX · ASCIMINIB HYDROCHLORIDE EQ 40MG BASE · TABLET, ORAL · Prescription
- SCEMBLIX · ASCIMINIB HYDROCHLORIDE EQ 100MG BASE · TABLET, ORAL · Prescription
- SCEMBLIX · ASCIMINIB HYDROCHLORIDE EQ 20MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Asciminib" as an intervention, any sponsor and status, largest first.
- A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05456191 · 568 participants · Start Nov 21, 2022 · Primary completion May 15, 2025
Drug: Asciminib; Nilotinib · For: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Sites: Denver, Colorado; Peoria, Illinois; Saint Paul, Minnesota · 119 sites in all
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04971226 · 405 participants · Start Oct 6, 2021 · Primary completion Nov 28, 2023
Drug: Imatinib; Nilotinib and 3 more · For: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Sites: Denver, Colorado; Fort Myers, Florida; Tallahassee, Florida · 110 sites in all
- Asciminib Roll-over StudyRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04877522 · 347 participants (planned) · Start Aug 30, 2022 · Primary completion Aug 30, 2030
Drug: Asciminib single agent; Imatinib and 4 more · For: Chronic Myelogenous Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sites: Ann Arbor, Michigan; St Louis, Missouri; New York, New York · 88 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02081378 · 326 participants · Start Apr 24, 2014 · Primary completion Jun 3, 2021
Drug: Asciminib (ABL001); Nilotinib and 2 more · For: Chronic Myelogenous Leukemia; Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Sites: Boston, Massachusetts; Ann Arbor, Michigan; New York, New York · 18 sites in all
- Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03106779 · 233 participants · Start Oct 26, 2017 · Primary completion May 25, 2020
Drug: Asciminib; Bosutinib · For: Chronic Myelogenous Leukemia
Sites: Chicago, Illinois; Beech Grove, Indiana; Baltimore, Maryland · 88 sites in all
- Asciminib Frontline Risk AdaptedNot yet recruiting
Prof. Dr. med. Andreas HochhausAcademic, hospital or other
NCT07804901 · 200 participants (planned) · Start Jan 1, 2027 · Primary completion Dec 31, 2030
Drug: Dasatinib 80mg QD (5 days per week); Standarc of Care · For: Chronic Myeloid Leukemia (CML)
Sites: Jena, Germany
- Asciminib Treatment Optimization in ≥ 3rd Line CML-CPPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04948333 · 199 participants · Start Oct 13, 2021 · Primary completion Mar 12, 2024
Drug: ABL001 40mg BID; ABL001 80mg QD and 1 more · For: Chronic Myelogenous Leukemia
Sites: CABA, Argentina; Buenos Aires, Argentina; Graz, Austria · 48 sites in all
- PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLPivotal-lookingRecruiting
Gruppo Italiano Malattie EMatologiche dell'AdultoAcademic, hospital or other
NCT06409936 · 160 participants (planned) · Start Jun 26, 2025 · Primary completion Jun 2029
Drug: Asciminib; Nilotinib · For: CML, Chronic Phase; Chronic Myeloid Leukemia, Chronic Phase; Chronic Myeloid Leukemia, BCR/ABL-Positive and 1 more
Sites: Barcelona, Spain; Bilbao, Spain; Girona, Spain · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue265
- death201
- nausea185
- drug ineffective179
- thrombocytopenia171
- drug intolerance141
- headache141
- diarrhoea138
- rash110
- pleural effusion109
- hypertension106
- arthralgia104
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 14 |
| 2020 | 22 |
| 2021 | 33 |
| 2022 | 412 |
| 2023 | 556 |
| 2024 | 716 |
| 2025 | 934 |
| 2026 | 801 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Scemblix (Asciminib Hydrochloride)
2024 spending
$197M
Beneficiaries
1,314
8,072 claims
Per beneficiary
$150,066
$351.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $2,112,304 |
| 2022 | $52,486,018 |
| 2023 | $114,488,117 |
| 2024 | $197,186,980 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A, Wang J, Kim DW, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Hughes TP, Mauro MJ, Cortes JE, et al. · N Engl J Med 2019 · Clinical Trial, Phase I, Multicenter Study
- Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.
Cortes JE, Hughes TP, Wang J, et al. · Blood 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
Luskin MR, Murakami MA, Keating J, et al. · Blood 2025 · Clinical Trial, Phase I, Multicenter Study
- Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A, Réa D, Boquimpani C, et al. · Leukemia 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D, Mauro MJ, Boquimpani C, et al. · Blood 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.